ArticleThe New England journal of medicine2015
Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- High tumor mutational burden and PIK3CA mutations correlate with poor Merkel cell carcinoma-specific survival.JCI insight · 2026Article
- Understanding Merkel Cell Carcinoma: Pathogenic Signaling, Extracellular Matrix Dynamics, and Novel Treatment Approaches.Cancers · 2025Review
- Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.International journal of molecular sciences · 2024Review
- Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.International journal of molecular sciences · 2024Review
- Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities.Cell reports. Medicine · 2023Article
- Review
- An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response.Cancer medicine · 2021Article
- Article
- Merkel Cell Polyomavirus and Merkel Cell Carcinoma.Cancers · 2020Review
- Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.Scientific reports · 2020Article
- Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.Dermatology and therapy · 2019Review
- A rare case of Merkel cell carcinoma with ovarian metastasis.Gynecologic oncology reports · 2019Article
- Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma.Neoplasia (New York, N.Y.) · 2019Article
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.Journal of cancer research and clinical oncology · 2019Review
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.Nature reviews. Clinical oncology · 2018Review
- Article
- [Merkel cell carcinoma: cutaneous manifestation of a highly malignant pre-/pro-B cell neoplasia? : Novel concept about the cellular origin of Merkel cell carcinoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- Merkel Cell Carcinoma Therapeutic Update.Current treatment options in oncology · 2016Review
- Unexpected maspin immunoreactivity in Merkel cell carcinoma.Diagnostic pathology · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.